Glaukos Corporation (GKOS) Stock Price & Analysis
Glaukos Corporation (GKOS) — MoonshotScore 38/100 (Weak band), calculated Nov 22, 2026. Price $237.31 (-0.33%), as of the Nov 20, 2026 trading session; market cap $14.1B.
Educational signal · not a buy or sell recommendation · How to read this
Glaukos Corporation · GKOS · NYSE · Healthcare · Medical - Devices
Research dated 2026-09-13: Glaukos sells ophthalmic therapies built around micro-scale implants: glaucoma stents used with cataract surgery, a standalone stent system for refractory disease, and targeted drug delivery through iDose TR. The case depends on whether rapid product-revenue growth and rich gross profit can outpace research and commercial spending long enough to produce durable operating profit and cash generation.
Price as of Nov 20, 2026
Key Statistics
MoonshotScore v2 · Glaukos (GKOS)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality and a strong balance sheet, but an expensive valuation. The score also carries a risk penalty for losses on top of negative retained earnings. Business Quality: Solid; Financial Safety: Sound; Valuation: Rich; Growth Durability: Growing; Momentum: Surging.
- EPS beat 1 of the last 4 reports
- Altman Z 31.44 · Piotroski F 4
- ROE -22.8% · ROA -3.9% · current ratio 4.57
Helping: business quality, balance-sheet strength, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 39 | Weak | |
| 38 | Weak | |
| 38 | Weak | |
| 38 | Weak | |
| 38 | Weak | |
| 38 | Weak |
The score was 38 in the stored Nov 21, 2026 snapshot and remains 38 in the current publication computed Nov 22, 2026 (0); the largest pillar moves were Momentum +1; the pillar moves offset under the sector-relative weighting, so the headline score is unchanged. This current publication is not yet represented in the immutable snapshot archive.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $237.31 | |
| Change on the day | -0.33% | |
| 52-week range | $87.32–$255.19 | |
| Market capitalisation | $14.1B | |
| Price / earnings (trailing) | 353.54 | |
| Shares traded on the day | 1.09M | |
| Beta (volatility vs the S&P 500) | 0.69 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for Glaukos (GKOS): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
4 lenses, 4 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 22, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 20, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
One of these lenses reads this company more favourably than the MoonshotScore does: Dalio-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
The Munger lens reads the current price as fairly valued against its own estimate of value.
Readings on this page are from Nov 22, 2026, except a card that shows its own read date.
What is Glaukos (GKOS), and what does it report?
Short answer · as of
Glaukos is not merely a surgical-device manufacturer. Its portfolio spans implanted glaucoma devices and sustained pharmaceutical delivery, with ophthalmologists adopting the products through procedure-based care and the company reaching customers through direct sales and distributors.
Research dated 2026-09-13.
Reported revenue is consolidated product revenue rather than a current platform-by-platform scorecard. A historical segment view was dominated by glaucoma, with corneal health much smaller, so the economic engine remains adoption of glaucoma therapies even as the broader pipeline reaches into corneal and retinal disease.
What do the latest results show for Glaukos (GKOS)?
Research dated 2026-09-13.
Revenue has risen across successive reported periods and accelerated sharply in the latest period. Gross profit advanced faster than operating expenses, allowing the operating loss to narrow even as research and commercial spending climbed; the net result nevertheless remained negative.
Recent reported revenue has also exceeded consensus repeatedly, while adjusted earnings have generally compared favorably with expectations. The observable mechanism is stronger aggregate product demand through Glaukos's sales channels; the consolidated figures do not support assigning the acceleration to a particular therapy.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2025 | $134M | -$16M | -$0.28 (diluted) |
| Q4 FY2025 | $143M | -$134M | -$2.32 (diluted) |
| Q1 FY2026 | $151M | -$20M | -$0.34 (diluted) |
| Q2 FY2026 | $186M | -$18M | -$0.31 (diluted) |
What are the financial strengths and risks for Glaukos (GKOS)?
Short answer
The MoonshotScore pillars rate business quality, balance-sheet strength, positive momentum as strengths.
Research dated 2026-09-13.
Liquidity is the clearest financial strength. Cash and short-term investments exceed total debt, the cash balance rose from the preceding period, and recent annualized cash use suggests substantial funding capacity if the current burn profile holds.
Cash conversion is not yet dependable: operating cash flow has alternated between positive and negative periods, annual net losses have expanded, and trailing operating and net margins remain below zero. High gross margin offers operating leverage, but research and selling costs still absorb more than the gross profit left after product costs.
Valuation adds a separate risk. Net cash is modest beside the company's market value, while price-to-sales and price-to-book ratios imply that investors already attach considerable value to future adoption and profitability.
Data-derived red flags
- Negative return on equity (-22.8%) — the business is not currently generating profit on shareholder capital.
- Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
- Rich valuation — a P/E of 353.54 runs well above the Healthcare sector’s ~20.60x, leaving little room for a miss.
What should you watch next at Glaukos (GKOS)?
Short answer · as of
The stored analyst-target capture is expired, so a current target watchpoint is unavailable.
Research dated 2026-09-13.
Watch whether revenue holds near the newly elevated run rate, gross margin preserves its recent improvement, and operating losses keep narrowing while research and selling costs rise. Positive operating cash flow would carry more weight if it persists rather than continuing the recent alternating pattern.
Consensus expects revenue to retreat from the latest peak while the loss per share narrows at the forthcoming report. Longer-range estimates assume continued revenue expansion and eventual positive earnings, making delivery against that progression a practical test of whether commercial scale is catching up with spending.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
Checked against the records this page reads, on the dates shown above.
How does Glaukos compare with its peers?
Short answer
Glaukos's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
Glaukos combines procedure-linked glaucoma stents with sustained intraocular drug delivery on a shared micro-scale platform. That hybrid model differs from a conventional device company because adoption can come from cataract-associated implants, standalone intervention for refractory glaucoma, or recurring therapeutic delivery rather than from a single hardware cycle.
Its current financial profile is equally distinctive: high gross margin and fast revenue expansion coexist with persistent research intensity, operating losses, and uneven cash generation. The business is therefore being valued less on present earnings than on the platform's ability to spread commercial and development costs across a growing ophthalmic portfolio.
| Company | Price | Market value | Score |
|---|---|---|---|
| $24.73 Nov 20, 2026 | $7.68B | 97 5-pillar Nov 22, 2026 | |
| $66.89 Nov 20, 2026 | $8.86B | 95 5-pillar Nov 22, 2026 | |
| $319.12 Nov 20, 2026 | $12.6B | 93 5-pillar Nov 22, 2026 | |
| $79.32 Nov 20, 2026 | $29.6B | 93 5-pillar Nov 22, 2026 | |
| $255.76 Nov 20, 2026 | $24.8B | 88 5-pillar Nov 22, 2026 | |
| $29.83 Nov 20, 2026 | $12.5B | 85 5-pillar Nov 22, 2026 | |
| $133.17 Nov 20, 2026 | $9.24B | 85 5-pillar Nov 22, 2026 | |
| $155.17 Nov 20, 2026 | $10.9B | 83 5-pillar Nov 22, 2026 | |
| $101.10 Nov 20, 2026 | $19.1B | 80 5-pillar Nov 22, 2026 | |
| $28.61 Nov 20, 2026 | $28.0B | 79 5-pillar Nov 22, 2026 | |
| $358.90 Nov 20, 2026 | $9.65B | 78 5-pillar Nov 22, 2026 | |
| $56.46 Nov 20, 2026 | $8.62B | 59 5-pillar Nov 22, 2026 | |
| Glaukos (GKOS) — this page | $237.31 | $14.1B | 38 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Last captured analyst target range, low to high (expired, captured Nov 18, 2026)
- $150.00 – $255.00
- Last captured analyst target (expired, captured Nov 18, 2026)
- $225.55
- Last captured median analyst target (expired, captured Nov 18, 2026)
- $240.00
Historical target record · Captured · Capture expired; not a current watchpoint.
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 12, 2026
- Transactions
- 97
- Identified insiders
- 11
- Purchases
- 0
- Sales
- 38
- Other transactions
- 59
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held GKOS in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported GKOS in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
Common Questions About GKOS (Healthcare)
Research dated 2026-09-13; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
How is iDose TR different from the iStent family?
The iStent family improves fluid outflow through implanted micro-bypass devices, while iDose TR uses an injectable implant to deliver glaucoma medication inside the eye. Glaukos therefore participates in glaucoma care through mechanical intervention and targeted pharmaceutical delivery.
Does Glaukos depend on cataract surgery for glaucoma adoption?
The established iStent products are inserted during cataract surgery, tying that part of the portfolio to procedure volumes and physician selection. iStent Infinite is intended for standalone use in refractory glaucoma, while iDose TR adds a drug-delivery route outside the cataract-linked stent model.
Why is Glaukos still losing money while revenue is rising?
Research and selling costs continue to consume the company's substantial gross profit. Revenue growth has recently narrowed the operating loss, but annual net losses and trailing margins show that scale has not yet produced sustained profitability.
Can Glaukos fund expansion of iDose TR and iStent Infinite?
Cash and short-term investments exceed debt, and the recent burn-rate cross-check indicates ample runway if spending and cash conversion remain comparable. Uneven operating cash flow and persistent losses mean that capacity depends on continued commercial progress and cost discipline.
What is the GKOS stock price today?
The last price recorded for Glaukos Corporation (GKOS), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the GKOS price target?
The last analyst consensus price target we captured for Glaukos Corporation (GKOS), with its FMP capture date, is listed under Analyst targets & estimates on this page. That capture has expired, so read it as historical, not as a current target. Targets are analyst opinions, not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 20 figures on this page — 1 from SEC filings and earnings calls, 15 from Financial Modeling Prep (FMP), 2 with no recorded source and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources (as of 2026-09-13), by section of the research
ETFs that hold GKOS
Funds in our ETF coverage that list GKOS among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| iShares Russell 2000 ETF (IWM) | 0.33% |